3651 results for «211»
3651 results
Diversity in coronary artery disease treatment
22 May 2026 – From EuroPCR 2026
Focusing on the diversity in coronary artery disease treatment, this session highlights challenges ranging from maintaining interventional cardiology services during conflict to the influence of comorbidities such as type 2 diabetes mellitus on prognosis and risk assessment. It also presents clinical outcomes related to stent thrombosis...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
News from drug-eluting therapies in 2026
19 May 2026 – From EuroPCR 2026
This session presents the latest advancements in drug-eluting therapies for 2026, including predictors of target lesion failure after drug-coated balloon treatment, clinical outcomes related to stenting length, and novel insights into sirolimus transfer evidenced by in vivo OCT imaging.
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
CTO ADVANCED Level III: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced educational session features live complex chronic total occlusion (CTO) PCI cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel. It emphasizes optimizing strategy selection, procedural efficiency across diverse CTO anatomies, and integrating advanced techniques into routine complex practice.
CTO ADVANCED Level I: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced level I CTO session features live educational cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel, focusing on structured procedure analysis, imaging-based planning, and integrated CTO techniques. Detailed case presentations and live procedural demonstrations underscore strategies for success in complex CTO interventions.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024